Sign Out
Azipac is active against most strains of the following Gram Positive and Gram Negative organisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae; Haemophilus influenzae and parainfluenzae, Moraxella catarrhalis, Bacteroides fragilis; Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Haemophilus ducreyi, Neisseria gonorrhoeae and Chlamydia trachomatis. Azipac also demonstrates in vitro activity against Legionella pneumophila, Mycoplasma pneumoniae and hominis, Campylobacter, Toxoplasma gondii, Treponema pallidum, Ureaplasma urealyticum.
Azipac is indicated for the treatment of: Upper respiratory tract infections including Pharyngitis, Tonsillitis, Sinusitis.
Lower respiratory tract infections including bronchitis and pneumonia.
Sexually transmitted diseases including non-gonococcal urethritis and cervicitis.
Otitis media.
Skin and skin structure infection.
